Two-stage interaction of the tumor nursing galectin-1 with the antiangiogenic peptide anginex

被引:0
作者
Zsófia Hegedüs
Edit Wéber
Lea Végh
Balázs Váczi
Vilmos Tubak
Éva Kriston-Pál
Zoltán Kele
Éva Monostori
Tamás A. Martinek
机构
[1] University of Szeged,SZTE
[2] Biological Research Center of the Hungarian Academy of Sciences,MTA Lendulet Foldamer Research Group, Institute of Pharmaceutical Chemistry
[3] University of Szeged,Lymphocyte Signal Transduction Laboratory, Institute of Genetics
[4] University of Szeged,Department of Medical Chemistry
来源
Journal of Thermal Analysis and Calorimetry | 2015年 / 120卷
关键词
Isothermal titration calorimetry; Anginex; Galectin-1; Angiogenesis;
D O I
暂无
中图分类号
学科分类号
摘要
The 33mer peptide anginex is a potent inhibitor of angiogenesis and tumor growth. Its biological activity is dependent on the β-galactoside-binding protein galectin-1 (gal-1), which has been reported to be the main receptor for anginex. The gal-1–anginex interaction has been observed using surface plasmon resonance and mass spectrometric methods, but the stoichiometry and affinity in the solution remain elusive. Our aim was to characterize the gal-1–anginex interaction via isothermal titration calorimetry. In order to ensure protein purity and integrity, native gel electrophoresis, Western blot analysis, mass spectrometric measurements, and ultracentrifugation were carried out for the recombinant wild-type human gal-1 and V5D gal-1 expressed in E. coli. Two stages were identified in the titration curves: (i) formation of a 4:1 galectin-1–anginex complex with low nM affinity, and (ii) a complex with 1:1 stoichiometry exhibiting KD > 200 nM. The 4:1 complex was robust at different concentrations, and neither the oxidation state nor the V5D mutation (a monomeric gal-1 mutant) of gal-1 affected this stoichiometry. The presence of the high-affinity 4:1 interaction may have implications for the biological applications of anginex.
引用
收藏
页码:449 / 456
页数:7
相关论文
共 152 条
[1]  
Griffioen AW(1998)Angiogenesis, a target for tumor therapy J Lab Clin Med 132 363-368
[2]  
Barendsz-Janson AF(2000)Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 52 237-268
[3]  
Mayo KH(2006)Antiangiogenic peptides and proteins: from experimental tools to clinical drugs Biochim Biophys Acta 1765 155-177
[4]  
Hillen HF(2007)Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Trends Cardiovasc Med 17 171-176
[5]  
Griffioen AW(2001)Anginex, a designed peptide that inhibits angiogenesis Biochem J 354 233-242
[6]  
Molema G(2002)The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models FASEB J 16 1991-1993
[7]  
Ruegg C(2006)Anti-angiogenesis and anti-tumor activity of recombinant anginex Biochem Biophys Res Commun 349 1073-1078
[8]  
Hasmim M(2003)Anti-tumor activity of the novel angiogenesis inhibitor anginex Cancer Lett 194 55-66
[9]  
Lejeune FJ(2007)NMR solution structure of the angiostatic peptide anginex Biochim Biophys Acta 1774 645-651
[10]  
Alghisi GC(1998)Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities Biochim Biophys Acta 1425 81-92